Assessment of the Impact of the Rotavirus Vaccine Against Severe Rotaviral Diarrhea in Uzbekistan
- PMID: 37300641
- PMCID: PMC10257161
- DOI: 10.1007/s44197-023-00126-z
Assessment of the Impact of the Rotavirus Vaccine Against Severe Rotaviral Diarrhea in Uzbekistan
Abstract
Background: This article presents the results of a long-term study of the impact of rotavirus vaccination in Uzbekistan. Uzbekistan is the first country in the Central Asian region to introduce rotavirus vaccination into the national compulsory vaccination calendar. The study aimed to evaluate the impact of rotavirus vaccination on hospitalizations due to all-cause AGE and RVGE in children < 5 years of age in Uzbekistan.
Methods: Detection of rotavirus antigen was performed using Rotavirus-Antigen-IFA-BEST "Vector Best" kit (Novosibirsk, Russia).
Results: The total of 20,128 children under 5 years of age were hospitalized in sentinel hospitals with a diagnosis of acute gastroenteritis during the study period (2019-2020). Of this number of children, 4481 children (22.2%) were included in the study. Of 4481 children, 367 (8.2%) children tested positive for rotavirus. In our study, decrease in the rotavirus rate was noted in all age groups. The peak of rotavirus positivity occurred in the months of January and February.
Conclusion: The average rotavirus-positive rate in the period (2019-2020) was 8.2% and the absolute percentage decrease was 18.1% compared to the pre-vaccination period (2005-2009) where the rotavirus-positive rate was 26.3%. The percentage of prevented cases averaged 68.8%.
Keywords: AGE; Bukhara; RVGE; Rotavirus; Tashkent; UMV; Vaccination.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Written informed consent was collected from all participants. Anonymity and confidentiality were confirmed.
Figures
Similar articles
-
Rotavirus vaccine effectiveness and impact in Uzbekistan, the first country to introduce in central Asia.Hum Vaccin Immunother. 2021 Feb 1;17(2):503-509. doi: 10.1080/21645515.2020.1776034. Epub 2020 Aug 5. Hum Vaccin Immunother. 2021. PMID: 32755429 Free PMC article.
-
Early impact of rotavirus vaccination in children less than five years of age in Mozambique.Vaccine. 2018 Nov 12;36(47):7205-7209. doi: 10.1016/j.vaccine.2017.10.060. Epub 2017 Nov 8. Vaccine. 2018. PMID: 29128381
-
Epidemiology and burden of rotavirus disease in Central Asia.Int J Infect Dis. 2011 Jul;15(7):e464-9. doi: 10.1016/j.ijid.2011.03.014. Epub 2011 Apr 27. Int J Infect Dis. 2011. PMID: 21524932
-
A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects.Expert Rev Vaccines. 2021 Dec;20(12):1499-1514. doi: 10.1080/14760584.2020.1853532. Epub 2021 Apr 20. Expert Rev Vaccines. 2021. PMID: 33275065 Review.
-
A Systematic Review of the Effect of Rotavirus Vaccination on Diarrhea Outcomes Among Children Younger Than 5 Years.Pediatr Infect Dis J. 2016 Sep;35(9):992-8. doi: 10.1097/INF.0000000000001232. Pediatr Infect Dis J. 2016. PMID: 27254030 Review.
References
-
- World Health Organization. Generic portocols for (i) hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children and (ii) a community-based survey on utilization of health care services for gastroenteritis in children: field test version. Geneva, 2002; WHO/V&B/02.15, 67 p.
-
- Jirakovskaya, EV, Ignatiev GM, Indikova IN, Tikunova NV. Evaluation of the new ELISA test system Rotavirus-antigen-ELISA-BEST. BIOpreparations. Prevention, diagnosis, treatment. 2009;3–4:35–36.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical